Research Article
Glucose Metabolism Changes in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals
Table 1
Baseline parameters of the study cohort by degrees of fibrosis.
| | | F0-F2 (Metavir)
N=118
Absolute (relative)
counts or mean ± SEM | F3 (Metavir)
N=80
Absolute (relative)
counts or mean ± SEM | F4 (Metavir)
N=170
Absolute (relative)
counts or mean ± SEM | P |
| | Male sex | 58 (49.2) | 34 (42.5) | 75 (42.4) | 0.477 |
| | Age (years) | 53.64±1.339 | 60.56±1.297 | 61.08±0.743 | <0.0001 |
| | Duration of HCV infection (years) | 9.37±0.72 | 10.82±0.75 | 11.06±0.59 | 0.158 |
| | BMI | 26.17±0.50 | 27.96±0.51 | 26.94±0.35 | 0.037 |
| | genotype 1b | 93 (78.8) | 73 (91.3) | 149 (87.6) | 0.002 | | genotype 1a | 14 (11.9) | 5 (6.3) | 4 (2.4) | | genotype 1 (unspecified) | 4 (3.4) | 2 (2.5) | 13 (7.6) | | genotype 3 | 7 (5.9) | 0 | 4 (2.4) | | genotype other | 0 | 0 | 0 |
| | Naïve | 53 (44.9) | 14 (17.5) | 43 (25.3) | <0.0001 | | Experienced | 65 (55.1) | 66 (82.5) | 127 (74.7) |
| | Relapse | 19 (32.2) | 35 (56.5) | 38 (30.9) | 0.009 | | Partial response | 9 (15.3) | 7 (11.3) | 14 (11.4) | | Breakthrough | 5 (8.5) | 8 (12.9) | 14 (11.4) | | Nonresponse | 26 (44.1) | 12 (19.4) | 57 (56.3) |
| | HBsAg positive | 3 (2.5) | 0 | 1 (0.6) | 0.166 |
| | HIV positive | 0 | 0 | 0 | N/A |
| | Treatment for hypertension | 33 (30.3) | 35 (46.7) | 72 (47.1) | 0.015 |
| | Treatment for dyslipidemia | 7 (6.4) | 11 (14.7) | 41 (26.8) | <0.0001 |
| | Treatment for T2DM | 12 (10.2) | 12 (15.0) | 34 (20.0) | 0.078 |
| | Diet only | 2 (20) | 5 (55.6) | 8 (30.8) | 0.024 | | OAD only | 5 (50) | 4 (44.4) | 4 (15.4) | | Insulin | 3 (30) | 0 | 14 (53.8) |
| | Extrahepatic manifestations | 23 (19.5) | 10 (12.5) | 15 (8.8) | 0.03 |
| | HCC | 1 (0.8) | 2 (2.5) | 5 (2.9) | 0.475 |
|
|
